Colorectal Cancer Clinical Trial
Official title:
Effects Of Standard And/Or Glutamine Dipeptide And/Or Omega-3 Fatty Ascid-Supplemented Parenteral Nutrition On Neutrophil Functions, Interleukin-8 Level And Length Of Stay-A Double Blind,Controlled, Randomized Study
Hypercatabolism and immune suppression are frequently seen in patients with malignancy. Preoperative nutritional state is an important factor in determining surgical and postoperative complications because the preoperative nutritional status affects the postoperative nutritional state, immunity and inflammatory response. In these patients, standard parenteral nutrition may not be sufficient to maintain the immunity and provide positive or stabilized nitrogen balance. Preoperative and perioperative supplementation with immune-enhancing enteral nutrition has been reported to increase total lymphocytes and T lymphocytes and decrease circulating levels of interleukin 6 and tumor necrosis factor- alfa. There is a report which showed that glutamine dipeptide supplemented parenteral nutrition improved the cellular and humoral immune functions. The investigators aimed to evaluate the effect of postoperative glutamine-dipeptide and/or omega 3 fatty acid supplemented parenteral nutrition on the neutrophil functions and postoperative course of patients with colorectal cancer.
Purpose Hypercatabolism and immune suppression are frequently seen in patients with
malignancy.Preoperative nutritional state is an important factor in determining surgical and
postoperative complications because the preoperative nutritional status affects the
postoperative nutritional state, immunity and inflammatory response.In these patients,
standard parenteral nutrition may not be sufficient to maintain the immunity and provide
positive or stabilized nitrogen balance. Preoperative and perioperative supplementation with
immune-enhancing enteral nutrition has been reported to increase total lymphocytes and T
lymphocytes and decrease circulating levels of interleukin 6 and tumor necrosis factor-
alfa.There is a report which showed that glutamine dipeptide supplemented parenteral
nutrition improved the cellular and humoral immune functions. The investigators aimed to
evaluate the effect of postoperative glutamine-dipeptide and/or omega 3 fatty acid
supplemented parenteral nutrition on the neutrophil functions and postoperative course of
patients with colorectal cancer.
Condition Intervention Phase Malnutrition Colorectal Cancer Dietary Supplement:
Immunonutrition Phase 4
Study Type: Interventional Study Design: Prevention, Parallel Assignment, Double Blind
(Subject, Investigator), Randomized, N/A
Official Title: Effects Of Standard And/Or Glutamine Dipeptide And/Or Omega-3 Fatty
Ascid-Supplemented Parenteral Nutrition On Neutrophil Functions, Interleukin-8 Level And
Length Of Stay-A Double Blind,Controlled, Randomized Study
Primary Outcome Measure: Title: neutrophil functions Time Frame: perioperative,postoperative
third and seventh days for change in first seven days of hospital stay Description: For
comparison of four different nutrition on neutrophil functions in first seven days of
hospital stays.
Secondary Outcome Measures: Title: Length of stay Time Frame: Length of stay (participants
will be followed for the duration of hospital stay) for colorectal cancer patients which are
eligable for study study from january 2007 to january 2008 in one year period.
Description: For comparison of four different nutrition on length of stay (participants will
be followed for the duration of hospital stay)
Actual Enrollment: 36 Study Start Date: January 2007 Actual Study Completion Date: January
2008 Actual Primary Completion Date: January 2008
Arms Assigned Interventions Active Comparator: Control an isocaloric and iso-nitrogenous
standard parenteral nutrition
Dietary Supplement: Immunonutrition Parenteral nutrition provided 25-30 kcal/kg/day energy
and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid supplementation was 0.1-0.2
g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide supplementation. All nutrient
substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous
line
Experimental: Standard parenteral-glutamine (S-D) alanine-glutamine (aln-gln) (Dipeptiven)
supplemented parenteral nutrition (S-D group, n=8),
Dietary Supplement: Immunonutrition Parenteral nutrition provided 25-30 kcal/kg/day energy
and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid supplementation was 0.1-0.2
g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide supplementation. All nutrient
substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous
line
Experimental: Standard-Omega-3 fatty acid (S-O) Omega-3 fatty acid (Omegaven) supplemented
parenteral nutrition (S-O group, n=8)
Dietary Supplement: Immunonutrition Parenteral nutrition provided 25-30 kcal/kg/day energy
and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid supplementation was 0.1-0.2
g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide supplementation. All nutrient
substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous
line
Experimental: Standard-glutamine-omega 3 (S-D-O) ala-gln and omega 3 fatty ascid
supplemented parenteral nutrition (S-D-O group, n=10).
Dietary Supplement: Immunonutrition Parenteral nutrition provided 25-30 kcal/kg/day energy
and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid supplementation was 0.1-0.2
g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide supplementation. All nutrient
substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous
line
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |